Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance.

Trial Profile

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2014

At a glance

  • Drugs Almorexant (Primary) ; Zolpidem (Primary)
  • Indications Sleep disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 19 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 13 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 May 2011 Actual initiation date (May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top